You are right - there is also Fragile-X too, which has a bigger market than Retts i believe. (I am pretty sure Acadia will bring NNZ-2591 to market for Fragile X - would be leaving alot on the table not to).But I deliberately left out these from calculation as they are already licensed out. You can't acquire 100% of these indications buying Neuren. Karuna and the other Ph 2 NNZ-2591 the whole income stream is available to purchase. So is comparing like with like.
Bristol Myers to acquire Karuna for $14Billion, page-7
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$15.17 |
Change
-0.220(1.43%) |
Mkt cap ! $1.888B | |||
| Open | High | Low | Value | Volume |
| $15.45 | $15.45 | $15.03 | $6.517M | 428.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 7052 | $15.12 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.20 | 199 | 1 |
View Market Depth
| Last trade - 16.10pm 21/07/2025 (20 minute delay) ? |
| NEU (ASX) Chart |